You are here: Industry Insights > Libtayo

News List

Phase III Lung Cancer Trial Stopped Early Due to Significant Survival Improvement americanpharmaceuticalreview
April 29, 2020
Regeneron and Sanofi announced the primary endpoint of overall survival (OS) was met in a Phase 3 trial comparing the PD-1 inhibitor Libtayo® (cemiplimab).
Libtayo approved for CSCC in the EU, including through the NHS in the UK pharmaceutical-technology
July 04, 2019
Sanofi and Regeneron have announced that the European Commission (EC) has granted conditional approval to Libtayo (cemiplimab) for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), a form of skin cancer, who cannot be
Sanofi, Regeneron's Libtayo hits hot streak with EU green light, NICE backing fiercepharma
July 04, 2019
Sanofi and Regeneron’s Libtayo is two for two in the last two days—with European officials, that is.
Health Canada issues Notice of Compliance with Conditions (NOC/c) for Libtayo (cemiplimab), the first and only biologic for the treatment of advanced cutaneous squamous cell carcinoma (CSCC) firstwordpharma
April 12, 2019
CSCC is the second most common skin cancer in Canadai.
Regeneron's Libtayo is chugging along in skin cancer. Next stop? First-line lung fiercepharma
February 24, 2019
Regeneron CEO Len Schleifer has called its brand-new cancer drug Libtayo “the engine that could.” And Wednesday, those wondering, “could what?” got a glimpse at what the PD-1 latecomer has done so far.

Previous page 1 2 Next page